Cost-utility analysis of methylphenidate treatment for children and adolescents with ADHD in Brazil

Página do item simplificado
dc.contributorSistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSP
dc.contributor.authorMAIA, Carlos R.
dc.contributor.authorSTELLA, Steffan F.
dc.contributor.authorWAGNER, Flavia
dc.contributor.authorPIANCA, Thiago G.
dc.contributor.authorKRIEGER, Fernanda V.
dc.contributor.authorCRUZ, Luciane N.
dc.contributor.authorPOLANCZYK, Guilherme V.
dc.contributor.authorROHDE, Luis A.
dc.contributor.authorPOLANCZYK, Carisi A.
dc.date.accessioned2016-07-18T12:22:39Z
dc.date.available2016-07-18T12:22:39Z
dc.date.issued2016
dc.description.abstractObjective: To perform a cost-utility analysis on the treatment of attention deficit hyperactivity disorder (ADHD) with methylphenidate immediate-release (MPH-1R) in children and adolescents from Brazil. Method: A Markov model was constructed to compare MPH-1R vs. no treatment. A 24 -week naturalistic study was conducted to collect transition probabilities and utility data. Effectiveness was expressed as quality -adjusted life -years (QALY), and costs reported in 2014 international dollars (1$). The perspective was the Brazilian Unified Health System as payer, and the time horizon was 6 years. Results: Of 171 patients, 73 provided information at baseline, and 56 at week 24. Considering the MPH-1R monthly cost of 1$ 38, the incremental cost-effectiveness ratio (ICER) of treatment was 1$ 9,103/QALY for children and 1$ 11,883/QALY for adolescents. In two-way sensitivity analysis, considering one Gross National Product per capita (1$ 11,530) as willingness-to-pay,a cost of no-treatment lower than 1$ 45/month would render MPH-IR a cost-saving strategy. Discussion: MPH-1R treatment of children and adolescents is cost-effective for ADHD patients from the Brazilian public health system perspective. Both patients and the healthcare system might benefit from such a strategy.
dc.description.indexMEDLINE
dc.description.sponsorshipConselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq)
dc.description.sponsorshipConselho Nacional de Desenvolvimento Cientifico e Tecnologico (Edital MCT/CNPq/CT-Saude/MS/SCTIE/DECIT) [067/2009]
dc.description.sponsorshipHospital de Clinicas de Porto Alegre (HCPA)
dc.description.sponsorshipPorto Alegre, Brazil
dc.description.sponsorshipCoordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES)
dc.description.sponsorshipInstitute de Avaliacao de Tecnologia em Sande (IATS)
dc.description.sponsorshipUniversidade Federal do Rio Grande do Sul (UFRGS)
dc.identifier.citationREVISTA BRASILEIRA DE PSIQUIATRIA, v.38, n.1, p.30-38, 2016
dc.identifier.doi10.1590/1516-4446-2014-1516
dc.identifier.eissn1809-452X
dc.identifier.issn1516-4446
dc.identifier.urihttps://observatorio.fm.usp.br/handle/OPI/14370
dc.language.isoeng
dc.publisherASSOC BRASILEIRA PSIQUIATRIA
dc.relation.ispartofRevista Brasileira de Psiquiatria
dc.rightsopenAccess
dc.rights.holderCopyright ASSOC BRASILEIRA PSIQUIATRIA
dc.subjectAttention deficit hyperactivity disorder
dc.subjectcost-utility analysis
dc.subjectmethylphenidate
dc.subject.otherattention-deficit/hyperactivity disorder
dc.subject.otherdeficit hyperactivity disorder
dc.subject.otherquality-of-life
dc.subject.othereconomic-evaluation
dc.subject.otherhealth
dc.subject.otherchildhood
dc.subject.othersurvivors
dc.subject.otherschedule
dc.subject.othervalidity
dc.subject.othersystem
dc.subject.wosPsychiatry
dc.titleCost-utility analysis of methylphenidate treatment for children and adolescents with ADHD in Brazil
dc.typearticle
dc.type.categoryoriginal article
dc.type.versionpublishedVersion
dspace.entity.typePublication
hcfmusp.author.externalMAIA, Carlos R.:Univ Fed Rio Grande do Sul, Porto Alegre, RS, Brazil
hcfmusp.author.externalSTELLA, Steffan F.:IATS, Porto Alegre, RS, Brazil
hcfmusp.author.externalWAGNER, Flavia:Univ Fed Rio Grande do Sul, Porto Alegre, RS, Brazil
hcfmusp.author.externalPIANCA, Thiago G.:Univ Fed Rio Grande do Sul, Porto Alegre, RS, Brazil
hcfmusp.author.externalCRUZ, Luciane N.:IATS, Porto Alegre, RS, Brazil
hcfmusp.author.externalROHDE, Luis A.:Univ Fed Rio Grande do Sul, Porto Alegre, RS, Brazil
hcfmusp.author.externalPOLANCZYK, Carisi A.:Univ Fed Rio Grande do Sul, Porto Alegre, RS, Brazil; IATS, Porto Alegre, RS, Brazil
hcfmusp.citation.scopus15
hcfmusp.contributor.author-fmusphcFERNANDA VALLE KRIEGER
hcfmusp.contributor.author-fmusphcGUILHERME VANONI POLANCZYK
hcfmusp.description.beginpage30
hcfmusp.description.endpage38
hcfmusp.description.issue1
hcfmusp.description.volume38
hcfmusp.origemWOS
hcfmusp.origem.pubmed26375808
hcfmusp.origem.scieloSCIELO:S1516-44462016000100030
hcfmusp.origem.scopus2-s2.0-84961165978
hcfmusp.origem.wosWOS:000372944900006
hcfmusp.publisher.citySAO PAULO
hcfmusp.publisher.countryBRAZIL
hcfmusp.relation.referenceAmerican Psychiatric Association, 2000, DIAGN STAT MAN MENT
hcfmusp.relation.referenceAmerican Psychological Association, 2013, DIAGN STAT MAN MENT
hcfmusp.relation.referenceGilmore A, 2001, PHARMACOEPIDEM DR S, V10, P85, DOI 10.1002/pds.564
hcfmusp.relation.referenceDoshi JA, 2012, J AM ACAD CHILD PSY, V51, P990, DOI 10.1016/j.jaac.2012.07.008
hcfmusp.relation.referenceSwanson JM, 2001, J AM ACAD CHILD PSY, V40, P168, DOI 10.1097/00004583-200102000-00011
hcfmusp.relation.referenceFeeny D, 2002, MED CARE, V40, P113, DOI 10.1097/00005650-200202000-00006
hcfmusp.relation.referenceChan E, 2002, ARCH PEDIAT ADOL MED, V156, P504
hcfmusp.relation.referenceDonnelly M, 2004, AUST NZ J PSYCHIAT, V38, P592, DOI 10.1080/j.1440-1614.2004.01422.x
hcfmusp.relation.reference[Anonymous], 2003, CNS DRUGS
hcfmusp.relation.reference[Anonymous], 2010, J PUBLIC HLTH, DOI 10.1007/S10389-010-0315-0
hcfmusp.relation.referenceHusereau D, 2013, PHARMACOECONOMICS, V31, P361, DOI 10.1007/s40273-013-0032-y
hcfmusp.relation.referenceCruz L, 2013, J MENT HEALTH, V22, P111, DOI 10.3109/09638237.2012.759193
hcfmusp.relation.referencePetrou S, 2003, HEALTH ECON, V12, P697, DOI 10.1002/hec.775
hcfmusp.relation.referenceFerri C, 2004, SOC PSYCH PSYCH EPID, V39, P218, DOI 10.1007/s00127-004-0729-5
hcfmusp.relation.referenceBARKLEY RA, 1990, PEDIATRICS, V86, P184
hcfmusp.relation.referenceCOSTELLO EJ, 1985, J ABNORM CHILD PSYCH, V13, P579, DOI 10.1007/BF00923143
hcfmusp.relation.referenceRussell LB, 1996, JAMA-J AM MED ASSOC, V276, P1172, DOI 10.1001/jama.276.14.1172
hcfmusp.relation.referenceMaia CR, 2015, REV BRAS PSIQUIATR, V37, P67, DOI 10.1590/1516-4446-2014-1378
hcfmusp.relation.referenceVieira FS, 2009, REV ASSOC MED BRAS, V55, P672, DOI 10.1590/S0104-42302009000600011
hcfmusp.relation.referenceKieling C, 2011, LANCET, V378, P1515, DOI 10.1016/S0140-6736(11)60827-1
hcfmusp.relation.referenceFlisher AJ, 2010, PLOS MED, V7, DOI 10.1371/journal.pmed.1000235
hcfmusp.relation.referenceShimoda S, 2005, QUAL LIFE RES, V14, P1407, DOI 10.1007/s11136-004-6127-3
hcfmusp.relation.referenceThiruchelvam D, 2001, J AM ACAD CHILD PSY, V40, P922, DOI 10.1097/00004583-200108000-00014
hcfmusp.relation.referenceShreeram S, 2009, J AM ACAD CHILD PSY, V48, P35, DOI 10.1097/CHI.0b013e318190045c
hcfmusp.relation.referenceShimoda S, 2008, J PEDIAT HEMATOL ONC, V30, P563, DOI 10.1097/MPH.0b013e31816e231c
hcfmusp.relation.referenceJensen PS, 2005, AM J PSYCHIAT, V162, P1628, DOI 10.1176/appi.ajp.162.9.1628
hcfmusp.relation.referenceLima AFBD, 2013, REV BRAS PSIQUIATR, V35, P186, DOI 10.1590/1516-4446-2012-0989
hcfmusp.relation.referenceRavens-Sieberer U, 2006, PHARMACOECONOMICS, V24, P1199, DOI 10.2165/00019053-200624120-00005
hcfmusp.relation.referencePliszka S, 2007, J AM ACAD CHILD PSY, V46, P894, DOI 10.1097/chi.0b013e318054e724
hcfmusp.relation.referenceKaufman J, 1997, J AM ACAD CHILD PSY, V36, P980, DOI 10.1097/00004583-199707000-00021
hcfmusp.relation.referenceFletcher J, 2009, J MENT HEALTH POLICY, V12, P119
hcfmusp.relation.referenceBraun S, 2013, CLIN THER, V35, P673, DOI 10.1016/j.clinthera.2013.03.017
hcfmusp.relation.referenceCharach A, 2011, 12EHC003EF AG HEALTH
hcfmusp.relation.referenceHong JY, 2009, BMC PSYCHIATRY, V9, DOI 10.1186/1471-244X-9-15
hcfmusp.relation.referenceHorsman John, 2003, Health Qual Life Outcomes, V1, P54, DOI 10.1186/1477-7525-1-54
hcfmusp.relation.referenceHuntley Z, 2012, BMC PSYCHIATRY, V12, DOI 10.1186/1471-244X-12-223
hcfmusp.relation.referenceIBM Corp, 2012, REL 2012 IBM SPSS ST
hcfmusp.relation.referenceKing S, 2006, HEALTH TECHNOL ASSES, V10, pxiii
hcfmusp.relation.referenceKing S, 2006, Health Technol Assess, V10, piii
hcfmusp.relation.referenceLange H, 2014, J ATTEN DISORD
hcfmusp.relation.referenceLindner Leandro Mendonça, 2009, Rev Saude Publica, V43 Suppl 1, P62, DOI 10.1590/S0034-89102009000800010
hcfmusp.relation.referenceMaia CRM, 2011, 8 ANN M HTAI RIO DE, P145
hcfmusp.relation.referenceNarayan Sangeeta, 2004, Expert Rev Pharmacoecon Outcomes Res, V4, P625, DOI 10.1586/14737167.4.6.625
hcfmusp.relation.referenceRobb J. A., 2011, SCH MENTAL HLTH, V3, P169, DOI 10.1007/S12310-011-9057-6
hcfmusp.relation.referenceTaylor E, 2004, EUR CHILD ADOLESC S1, V13, P17, DOI 10.1007/s00787-004-1002-x
hcfmusp.relation.referenceVianna C, 2009, DIRETRIZES METODOLOG
hcfmusp.relation.referenceWorld Health Organization (WHO) Collaborating Centre for Drug Statistics Methodology (WHOCC), 2014, DDD DEF GEN CONS
hcfmusp.scopus.lastupdate2024-05-17
relation.isAuthorOfPublicationfd7b4c9d-b25c-4055-9d1c-771ab7517441
relation.isAuthorOfPublication107c1ba9-764d-461e-aa8d-0dee86ca590e
relation.isAuthorOfPublication.latestForDiscoveryfd7b4c9d-b25c-4055-9d1c-771ab7517441
Arquivos
Pacote Original
Agora exibindo 1 - 1 de 1
Imagem de Miniatura
Nome:
art_MAIA_Costutility_analysis_of_methylphenidate_treatment_for_children_and_2016.PDF
Tamanho:
1009.72 KB
Formato:
Adobe Portable Document Format
Descrição:
publishedVersion (English)
Baixar
Coleções
Artigos e Materiais de Revistas Científicas - FM/MPS
Artigos e Materiais de Revistas Científicas - LIM/21